

Disclaimer and notes



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES OR TO "US PERSONS" (AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")) OR INTO OR WITHIN AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION (THE "MATERIALS") IN JURISDICTIONS OUTSIDE THE UK SHOULD INFORM THEMSELVES ABOUT AND OBSERVE ANY APPLICABLE LEGAL REQUIREMENTS IN THEIR JURISDICTIONS. IN PARTICULAR, THE DISTRIBUTION OF THE MATERIALS MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS. ACCORDINGLY, RECIPIENTS REPRESENT THAT THEY ARE ABLE TO RECEIVE THE MATERIALS WITHOUT CONTRAVENTION OF ANY APPLICABLE LEGAL OR REGULATORY RESTRICTIONS IN THE JURISDICTION IN WHICH THEY RESIDE OR CONDUCT BUSINESS.

The information presented herein is not an offer for sale within the United States of any equity shares or other securities of Apax Global Alpha Limited ("AGA"). AGA has not been and will not be registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition, AGA's shares (the "Shares") have not been and will not be registered under the Securities Act or any other applicable law of the United States. Consequently, the Shares may not be offered or sold or otherwise transferred within the United States, or to, or for the account or benefit of, US Persons, except pursuant to an exemption from the registration requirements of the Securities Act and under circumstances which will not require AGA to register under the Investment Company Act. No public offering of the Shares is being made in the United States.

This document represents the quarterly report of AGA. It does not constitute an advertisement and is not a prospectus. It does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein in the United States or in any other jurisdiction, nor shall it, by the fact of its distribution, form the basis if, or be relied upon, in connection with any such contract. No offer, invitation or inducement to acquire Shares or other securities in AGA is being made by, or in connection with, this document.

The information and opinions contained in this document are for background purposes only, do not purport to be full or complete and do not constitute investment advice. Subject to AGA's regulatory requirements and responsibilities, no reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness and no representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this document by AGA or any of its affiliates and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. This information is not intended to provide, and should not be relied upon for accounting, legal, tax advice or investment recommendations. You should consult your tax, legal, accounting or other professional advisors about the issues discussed herein. The descriptions contained herein are summaries and are not intended to be complete and neither AGA nor any of its affiliates undertakes any obligation to update or correct any errors or inaccuracies in any of the information presented herein. The information in this document and any other information discussed at the presentation is subject to change. This document does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase any investment nor shall it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract thereof.

The Materials may include forward-looking statements. The words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding AGA's intentions, beliefs or current expectations concerning, among other things, AGA's results of operations, financial condition, liquidity, prospects, growth and strategies. The forward-looking statements in the Materials are based on numerous assumptions regarding AGA's present and future business strategies and the environment in which AGA will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of AGA to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond AGA's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as AGA's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which AGA operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. AGA expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in AGA's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of the Materials. Accordingly, undue reliance should

Note this presentation covers the period from 1 January 2016 to 31 December 2016 unless otherwise indicated.

The contents of this Presentation, which have been prepared by and are the sole responsibility of the Company, have been approved by Apax Partners LLP solely for the purposes of section 21(2)(b) of the Financial Services and Markets Act 2000, as amended (the "FSMA").

This Presentation is not intended to be marketing as defined in an EU jurisdiction under the EU's Alternative Investment Fund Managers Directive (2011/61/EU).

Date: 7 March 2017

Highlights



A divided year with strong performance in H2 2016 and largely flat performance in H1 2016

Adjusted NAV¹ at 31 December 2016

€938.7m/ £801.2m

Adjusted NAV per share at 31 December 2016

€1.91/£1.63

Dividends per ordinary share in respect of 2016 (€/£)

9.43c/8.08p

Market capitalisation at 31 December 2016

€804.8m/ £686.9m

Total NAV Return² FY 2016

6.6% (-0.6%/7.2%)³

% of funds invested at 31 December 2016

96%

Highlights in 2016

- Robust Total NAV Return of 6.6% in a market which was overshadowed by political and economic events
- Performance largely flat in H1 2016, but H2 2016 showed strong improvement with Total NAV Return of 7.2%
- Adjusted NAV per share increased to €1.91/£1.63, supported by portfolio currency exposure to the US dollar
- Dividends paid in line with AGA's dividend policy distributing c.5% of NAV to shareholders.
- Fund remained close to fully invested during the year
- Significant milestone achieved through commitment of c.\$350m into AIX

^{1.} Adjusted NAV represents NAV of €950.0m adjusted for the estimated performance fee reserve of €11.3m at 31 December 2016


^{2.} Total NAV Return for the year means the movement in the Adjusted NAV per share over the period plus any dividends paid. NAV per share used in the calculation is rounded to 5 decimal points


^{3.} Total NAV Return in H1 2016/Total NAV Return in H2 2016

Adjusted NAV development and performance









Highlights


- Adjusted NAV increased from €923.6m to €938.7m yielding a Total NAV Return of 6.6%
- Dividends totalling €45.9m were paid during the year
- All drivers of investment performance (income, realised and unrealised gains) contributed positively to value accretion
- Investment Manager's deliberate focus on attractive investment opportunities in the US also supported an FX gain of €24.5m or 2.7%

^{1.} See p.22 in the appendix for details regarding per share data

^{2.} Performance fee adjustment accounting for the movement in estimated performance fee reserve at 31 December 2016



Total value gains partially offset by losses in a select number of positions





^{1.} Total value calculated by taking non-portfolio specific performance fee reserve, FX and other expenses


^{2.} Total value calculated by taking unrealised and realised movements, FX and income earned during the year

^{3.} Summary of the 3 main contributors to gross gains and losses in the Private Equity portfolio and the Derived Investments portfolio

AGA invested portfolio at 31 December 2016








^{1.} Excludes cash and cash equivalents and net current assets, including these the NAV is €950.0m and Adjusted NAV adjusted for the estimated performance fee is €938.7m at 31 December 2016

^{2.} Inclusive of recallable distributions received from the Apax Funds










- Limited exposure
- Taking advantage of value opportunities in Brexit aftermath





- Portfolio overweight in US dollars
- High share of floating rate loans providing upside in rising rate environment

^{1.} Due to AGA's very small indirect exposure to GHG (€0.2m via AGA's investment in Apax Europe VI), GHG is not shown individually in the above. In addition, note that although Paradigm has regional headquarters located in the UK, the majority of the company's revenue is from outside Europe and is excluded from the above analysis on that basis





Private Equity activity in 2016



An active year with strong flow of realisations

Acquisition

Closed¹ in Q4 2016



Respiratory solutions joint venture with Becton Dickinson (AVIII, North America, Healthcare)

Announced¹ in Q4 2016



Leading European laboratory and radiology service Company (AIX⁴, Europe, Healthcare)

Q1 -Q3 2016

4 new investments

Engineering (AVIII, Europe, Tech & Telco)

Duck Creek

(AVIII, North America, Tech & Telco)

Invent-Neurax

(AVIII, Europe, Healthcare)


Boats Group

(AIX, North America, Services)


Divestment					
Closed – fully exi	ted ² in Q4 2016		Initial purchase year	MOIC ³	IRR ³
Sisal	Lotteries and gaming operator in Italy (AEVI, Europe, Consumer)	Sold to a financial acquirer	2006	(0.1x)	-20%
PLANTASJEN.	Garden superstore chain in the Nordic region (AEVII, Europe, Consumer)	Sold to a financial acquirer	2007	(0.7x)	-4%
Closed – partially	exited ² in Q4 2016				
\(\scential\)	International B2B media company (AEVII, Europe, Legacy Media)	Partial public market secondary sale	2008	(1.1x)	2%
\$ Chola	A top Indian non-bank financial company (AVIII, India, Services)	Exited via public markets: Sold c.65% of shares at year end and fully exited by January 2017	2014	2.7x) ⁵	54%)5
Closed – recapita	ilisation realisation ² in Q4 2016				
Global Logic	Outsource product development provider (AVIII, Rest of World, Tech & Telco)	Refinanced capital structure during 2016. Announced partial exit in January 2017	2013	(5.1x)	67%
Q1 –Q3 2016					
6 full exits	King, Rhiag, Auto Trader, Tommy Hill China, Trader Corporation and Epico			6.1 x 6	36 %
2 partial exits	Capio and Garda			(2.0x) ⁶	17 % 6
2 recapitalisation realisations	Evry and Ideal Protein			3.0 x ⁶	97 % 6

- 1. Vyaire Medical closed October 2016. Unilabs announced December 2016
- Sisal closed December 2016, Plantasjen closed November 2016, Ascential secondary sale closed December 2016, Chola secondary sale closed December 2016 and fully exited in January 2017, GlobalLogic recapitalisation closed December 2016 and partial exit announced January 2017
- 3. Gross MOICs and Gross IRRs represent return to the Apax Funds as at 31 December 2016, including unrealised value and total realised proceeds. Calculated since the initial purchase date of the investment.
- . The above is in reference to AIX's acquisition of a majority position in Unilabs, announced in December 2016 and closed in February 2017. AEVI will retain its existing minority stake initially acquired in 2007
- 5. Chola's Gross MOIC and IRR shown above is as at 31 December 2016 before the investment was fully exited
- 6. Gross MOIC and Gross IRR calculated on aggregated cashflows of each respective sub portfolio of exits

Private Equity Adjusted NAV development and performance









Highlights

- Adjusted NAV increased by €24.7m to €494.1m in the year
- Calls of €58.4m³ were related to Apax VIII which invested in 4 new investments in 2016. AIX's only closed investment during the year was bridge funded by AIX's capital call facility
- Strong flow of distributions from Apax Europe VI of €4.6m, Apax Europe VII of €25.9m, Apax VIII of €37.9m and AMI of €0.4m
- Unrealised gains largely due to robust operational performance and higher valuation multiples
- Total Return for the year of 6.6% translates in to a Gross IRR of 8.0% when taking in to account the timing of cash flows

^{1.} Performance fee adjustment accounting for the movement estimated performance fee reserve at 31 December 2016


^{2.} Gross IRR calculated based on cash flows to/from Apax Funds from/to AGA in 2016


^{3.} Including recalled distributions of €15.2m

Private Equity portfolio




Exposure remains stable with Idealista, Engineering and Invent Neurax now in the top ten





^{1.} On a look through basis reflecting AGA's investments in various Apax Funds 2. LTM: Last Twelve Months 3. Represents the weighted average of the respective metrics across the underlying portfolio companies using latest available information. 4. Represents investments and exits during the year ended at the indicated date. During 2016, there were eight closed full exits (King, Rhiag, Auto Trader, Tommy Hilfiger China, Sisal, Plantasjen, Epicor and Trader Corporation) and 4 closed partial exits represented by the partial secondary sales of Ascential, Capio, Chola and Garda shares. The above number of exits excludes the recapitalisation of Evry during Q2 2016, Ideal Protein during Q3 2016 and GlobalLogic during Q4 2016. See full details of investments on p.9.

Operating performance and portfolio age






2005-2009 2010-2012

201320142015

2016







Portfolio investment vintage

31 December 2016, in % of Private Equity NAV



• Commitment to Apax IX will over time result in greater vintage diversity

- Strong operational performance significantly driving value movements and/or valuation outlook
- Operational performance behind expectations impacting value and/or valuation outlook
- Weakened operational performance negatively contributing to value movements and/or valuation outlook





Derived Investment activity in Q4 2016

Strong IRR performance from exited investments in 2016



Acquisition Debt in Q4 2016 2 A prominent European laboratory and radiology service Company

(Europe, Healthcare)

Equity	in	Q4	2016
--------	----	----	------

6 new positions

The Investment Manager has started to acquire positions in six

Acquisitions in Q1-Q3 2016

10 new investments

4 in Debt6 in Equity

<u>Debt:</u> Cole Haan, Ellucian, Acelity, Vertafore

<u>Equity:</u> Edelweiss Financial Services, Fortinet Inc, Geometric Ltd, Palo Alto Networks Inc., Sophos, TAKE Solutions Ltd

Divestment				
Debt in Q4 2016	i e e e e e e e e e e e e e e e e e e e		Initial year of purchase	IRR ¹
НЕМА	A Dutch international discount retail chain with stores in Netherlands, Belgium, France and Germany (Europe, Consumer)	Senior secured floating rate note	2014	9%
Compuware,	A software company with products aimed at IT departments of large businesses (North America, Tech & Telco)	Second lien term loan	2014	21%
Debt – refinanci	ng in Q4 2016			
Acelity"	Medical equipment company (North America, Healthcare)	Second lien senior secured note	2015	19%
<u>Unilabs</u>	A prominent European laboratory and radiology service Company (Europe, Healthcare)	Second lien PIK note	2013	14%
Equity in Q4 201	16			
Chola	A significant non-bank financial company in India (India, Services)	Public equity investment	2014	80%
Divestments Q1	-Q3 2016			
13 divestments	Debt: Physiotherapy, Exact Holdings 1L, Berlin Packaging 2L, Peak 10 2L Equity: Zhaopin; Greene King PLC, Karur Vysya Bank Ltd, Sinopharm Group Co Ltd, Hinduja	4 debt positions and 9 equity positions		5 11%
	Global Solutions Ltd, Alkem Laboratories, LIC Housing Finance Ltd, Edelweiss Financial Services, Smart Technologies			

^{1.} Gross IRR calculated since the initial purchase date of the investment. For assets purchased prior to 15 June 2015, the IPO date, the IRR is calculated based on the initial purchase price in PCV

^{2.} AGA previously held an investment in Unilabs – this was refinanced in October 2016 and AGA increased its holding when investing in the new instrument. The original note was repaid in October 2016

[.] AGA acquired a newly issued second lien instrument in Acelity at the end of Q3 2016. The divestment above represents the original position purchased in December 2015 that was repaid in October 2016

^{4.} AGA realised the majority of Chola in Q4 2016, however, the final tranche of shares were sold on 19 January 2017. Gross IRR disclosed represents the full exit.


^{5.} Gross IRR calculated on aggregated cash flows of each respective sub-portfolio of exits

Derived Investments Adjusted NAV development and performance



Income remains a stable contributor to performance





Highlights

- Adjusted NAV decreased by €26.2m to €406.2m in 2016 mainly due to divestments exceeding new investments
- Total of €174.0m was invested into seventeen new investments
- Realisations of €204.1m consisted of €139.9m Derived Debt realisations and €64.2m Derived Equity realisations
- Total Return for the year of 6.0% mainly driven by income of €31.2m earned in the Derived Debt portfolio. This corresponds to a 2016 IRR of 8.3%
- Investment Manager's view that more attractive investment opportunities were to be found in the US supported FX gains, and resulted in higher US dollar exposure


^{1.} Performance fee adjustment accounting for the movement estimated performance fee reserve at 31 December 2016


^{2. 2016} Gross IRR calculated based on cash flows to and from Derived Investments in 2016

Performance of Derived Debt and Derived Equity

Both portfolios contributed to 2016's performance







Highlights

- Annual Gross IRR on the Derived Debt portfolio was 8.0% and 9.3% for the Derived Equity portfolio
- Derived Debt performance predominantly driven by continued income generation
- Three positions⁴ were responsible for over 80% of unrealised losses in the Derived Debt portfolio
- Larger FX gains were seen in the Derived Debt portfolio due to the large exposure to US dollar denominated debt, particularly floating rate instruments
- Derived Equity performance with positive contribution from all performance elements

^{1.} Performance fee adjustment accounting for the movement estimated performance fee reserve at 31 December 2016

^{2. 2016} Gross IRR calculated based on cash flows to and from Derived Debt in 2016


^{3. 2016} Gross IRR calculated based on cash flows to and from Derived Equity in 2016


^{4.} Answers, Fullbeauty and Rue 21

Derived Investments Portfolio



Debt yield to maturity at 12%, Derived Equity earnings strengthened with new additions





^{1.} GAV weighted average yield to maturity (YTM) of the Derived Investments Debt portfolio

[.] GAV weighted average of the current full year income (annual coupon/clean price as at 31 December 2016) for each debt position in the Derived Debt Investments at 31 December 2016

^{3.} GAV weighted average of latest available year-over-year LTM EBITDA growth of the underlying Derived Debt Investments

^{4.} GAV weighted average of latest available year-over-year LTM earnings growth of the underlying Derived Equity Investments

[.] GAV weighted average Price Earnings multiple of Derived Equity Investments

[.] New investments in the year ended 31 December 2016 - (this excludes 6 positions where the Investment Manager is actively looking to increase its position). See slide 14 for full list of acquisitions.

^{7.} Represents full exits during 2016. See p.14 for list of disposals.

Conclusions and Outlook



2016 performance

- Total NAV Return during year of 6.6%, reflects largely flat performance during H1, with strong performance in H2. Total NAV Return includes payment of two semi-annual dividends totalling 7.64 pence per share (equivalent to 2.5% of NAV at 31 December 2015 and 30 June 2016 respectively)
- The Private Equity funds delivered a strong flow of distributions during the year totalling €68.8m, Derived Investments portfolio delivered €32.5m of income and €204.1m of proceeds from disposals
- Strong returns generated on fully exited investments aggregate realised IRR of 29.9% for Private Equity and 13.2% for Derived Investments in 2016
- Performance benefited from the portfolio's large US dollar exposure

Private Equity outlook

- Valuations remain elevated as do economic and political risks (including unveiling of President Trump's agenda, outcome of Brexit negotiations, Dutch, French and German elections)
- Continued focus on early value creation through transformational ownership of businesses
- Buying right and ahead of the curve in subsectors that Apax Partners has sector expertise
- · Global approach provides additional flexibility to the investment strategy
- Expect Private Equity to remain slightly overweight following AGA's commitment to AIX

Derived Investments outlook

- In Derived Debt, interest rate increases are expected in the US following the recent presidential election
- Loan investments remain more attractive than public debt investments
- On the margin, listed equity investments may currently offer more attractive risk adjusted returns
- In Derived Equity, the expected US fiscal impulse could create opportunities amongst more cyclically exposed assets
- We continue to believe that India offers a broad range of attractive opportunities and remain cautious on China





The Investment Adviser

Apax Partners



Industry leader

Over €40 billion equivalent of funds raised to date

Pioneer in Private Equity

Established in 1969 in the US and 1972 in Europe¹

Significant global reach

8 offices in 7 countries

Deep bench of industry specialists


c.100 investment professionals

Industry focused investments

Tech & Telco Services
Healthcare Consumer







^{1.} AGA's target allocation will fluctuate over time due to market conditions and other factors, including calls for and distributions from Apax Funds, the timing of making and exiting Derived Investments and the Company's ability to invest in future Apax Funds



The Company

Apax Global Alpha Limited



About AGA

AGA is a closed ended investment company that invests in a diversified portfolio of Private Equity Investments and Derived Investments in debt and equities.

What AGA does

- > Set business objectives and investment strategy
- > Governance and risk management
- > Appointment and oversight of service providers

The Investment Manager

Apax Guernsey Managers Limited

About AGML

AGA has appointed Apax Guernsey Managers Limited ("AGML" or the "Investment Manager") as its discretionary Investment Manager. AGML is managed by a board of experienced investment professionals and operational private equity executives.

What AGML does

- > Discretionary portfolio management
- > Investment and divestment decisions
- > Portfolio performance analysis and risk management

The Investment Adviser

Apax Partners LLP



About Apax Partners

Apax Partners LLP is a leading global private equity advisory firm and acts as Investment Adviser to AGML. It operates globally and has more than 30 years of investing experience. Apax Partners has raised and advised funds that total over €40bn in aggregate at 31 December 2016.

What Apax Partners does

- > Identification and due diligence of investment opportunities
- > Recommendation of potential investments to AGML for consideration



Key financial highlights at 31 December 2016

Net Asset Values as at 31 December 2016 €m								
	31 Dec 2015	31 Mar 2016	30 Jun 2016	30 Sep 2016	31 Dec 2016			
NAV	936.5	887.1	901.1	897.2	950.0			
Adjusted NAV	923.6	883.6	894.4	889.6	938.7			
Private Equity	473.6	444.5	440.3	421.0	498.8			
Derived Investments	441.1	402.3	407.8	409.6	412.8			
Cash and Cash Equivalents	22.9	42.7	48.5	65.6	33.9			
Others	(1.1)	(2.4)	4.5	1.0	4.6			

Net Asset Values per share as at 31 December 2016 €/£								
	31 Dec 2015	31 Mar 2016	30 Jun 2016	30 Sep 2016	31 Dec 2016			
NAV per Share	€1.91/£1.41	€1.81/£1.43	€1.83/£1.53	€1.83/£1.58	€1.93/£1.65			
Adjusted NAV per Share	€1.88/£1.38	€1.80/£1.43	€1.82/£1.52	€1.81/£1.57	€1.91/£1.63			

Top 10 Portfolio Investments AGA's indirect exposure as at 31 December 2016							
	Fund	Sector	Valuation €m	% of NAV	% of invested portfolio		
Global Logic °	AVIII	Tech & Telco	51.3	5%	6%		
EVRY	AVIII	Tech & Telco	51.3	5%	6%		
o dželis	AVIII	Services	40.2	4%	4%		
AssuredPartners	AVIII	Services	36.5	4%	4%		
= exact	AVIII	Tech & Telco	34.1	4%	4%		
Onecallcare MANAGEMENT	AVIII & AEVII	Healthcare	22.2	2%	2%		
wehkamp	AVIII	Consumer	21.3	2%	2%		
<u>idealista</u>	AVIII	Consumer	20.0	2%	2%		
ENGINEERING	AVIII	Tech & Telco	19.7	2%	2%		
Invent Farma	AVIII	Healthcare	19.1	2%	2%		
Total Top 10			315.7	33%	34%		
Others			183.1	20%	21%		
Total Private Equ	uity		498.8	52%	55%		

Top 10 Portfolio As at 31 December 2016	Investments		De	erived Investments
	Instrument	NAV €m	% of NAV	% of invested portfolio
ellucian.	Second unsecured	31.1	3%	3%
Acelity	Second lien senior secured	30.9	3%	3%
fullbeauty	Second lien term loan	26.3	3%	3%
₩ Unilabs	Second lien PIK	21.0	2%	2%
genex.	Second lien term loan	21.0	2%	2%
Equity investment ¹	Listed equity	20.7	2%	2%
e azelis	Second lien term loan	20.4	2%	2%
AssuredPartners	Second lien term loan	19.2	2%	2%
ADVANTAGE	Second lien term loan	18.7	2%	2%
RentPath	Second lien PIK	18.5	2%	2%
Total Top 10		227.8	23%	23%
Others		185.0	21%	22%
Total Derived Inves	stments	412.8	44%	45%

^{1.} Name of position is not disclosed as AGA is considering position for further investment.






Adjusted NAV per share progression (€)

	Adjusted NAV/share at the beginning of the period	Income	Realised gains	Unrealised gains	FX	Dividend	Other	Adjusted NAV/share at end of the period	Return %	Total NAV Return %
Q3 2015	€1.79	€0.01	€0.00	-€0.01	-€0.01	€0.00	€0.00	€1.78	-0.4%	5.20/
Q4 2015	€1.78	€0.01	€0.01	€0.07	€0.02	€0.00	-€0.01	€1.88	5.6%	5.2%
Q1 2016	€1.88	€0.02	€0.00	€0.01	-€0.06	-€0.05	-€0.00	€1.80	-1.8%	
Q2 2016	€1.80	€0.02	€0.00	-€0.02	€0.03	€0.00	-€0.01	€1.82	1.2%	
Q3 2016	€1.82	€0.02	€0.00	€0.03	-€0.01	-€0.05	-€0.00	€1.81	2.0%	6.6%
Q4 2016	€1.81	€0.02	€0.00	€0.02	€0.07	€0.00	-€0.01	€1.91	5.2%	

Adjusted NAV per share progression (€)



Apax IX commitment






Item	Apax IX
Size	\$9bn
Sectors	
	Tech & Telco Services
	Healthcare Consumer
	Digital
Geographies	North America (c.30-50%) RoW


- During 2016, AGA committed c.\$350m to Apax IX ("AIX"), a \$9bn dual currency¹ Private Equity fund
- Commitment split approximately 50:50 between the euro and US dollar tranches
- AIX will follow a disciplined, global, sector-focused strategy of investing in buyout opportunities across the Tech & Telco, Services, Healthcare, and Consumer sectors
- AIX will draw on the Investment Adviser's digital expertise and Operational Excellence Practice to initiate and accelerate transformation amongst portfolio companies
- AIX has already announced two acquisitions during 2016²


^{1.} The two currencies are US dollars and euros




































Portfolio composition - Derived Investments














Portfolio composition - Derived Debt Investments







Shareholder information



FINANCIALS (at 31 December 2016)

Ticker code APAX Ordinary shares in issue 491,100,768

Adjusted net asset value €938.7m/ £801.2m Market capitalisation €804.8m/ £686.9m

Adjusted NAV per share €1.91/£1.63

BOARD OF DIRECTORS

Tim Breedon (Chairman)
Chris Ambler (Non-Executive Director)
Susie Farnon (Non-Executive Director)
Sarah Evans (Non-Executive Director)

INVESTMENT MANAGER

Apax Guernsey Managers Limited Third Floor Royal Bank Place 1 Glategny Esplanade St Peter Port Guernsey GY1 2HJ

INVESTMENT ADVISER

Apax Partners LLP 33 Jermyn Street London SW1Y 6DN

CONTACT DETAILS

Apax Global Alpha Limited P.O. Box 656 East Wing Trafalgar Court Les Banques St Peter Port Guernsey GY1 3PP +44 20 7872 6300

investor.relations@apaxglobalalpha.com

www.apaxglobalalpha.com

Endnotes



References to "Apax Funds"

Private Equity Funds advised by Apax Partners LLP to which AGA is committed are Apax IX - consisting of a euro tranche ("AIX – EUR") and a US Dollar tranche ("AIX – USD"), AMI Opportunities Fund ("AMI"), Apax VIII ("AVIII") – consisting of a euro tranche ("AVIII – EUR") and a US Dollar tranche ("AVIIII – USD"), Apax Europe VII ("AEVII") and Apax Europe VI ("AEVI"). In addition, reference is made to the Apax Buyout Funds which includes AIX, AVIII, AEVII, Apax US VII, L.P. ("USVII"), AEVI and Apax Europe V ("AEV"). Please note that throughout this presentation both the funds full name and abbreviated forms are used interchangeably.

Information with Respect to AGA Performance including Gross IRRs, Net IRRs and MOICs

"Gross IRR" as used throughout this Presentation, and unless otherwise indicated, means an aggregate, annual, compound, gross internal rate of return calculated on the basis of cash receipts and payments together with the valuation of unrealised investments at the measurement date. Foreign currency cash flows have been converted at the exchange rates applicable at the date of receipt or payment by the relevant entity.

For the Company's Private Equity Investments, Gross IRR is net of fees and carried interest paid to the underlying investment manager and/or general partner of the relevant fund. For Derived Investments, Gross IRR does not reflect expenses to be borne by the relevant investment vehicle or its investors including, without limitation, performance fees, management fees, taxes and organisational, partnership or transaction expenses. "Net IRR" means Gross IRR less any expenses borne by the relevant investment vehicle or its investors including, without limitation, carried interest, management fees, taxes and organisational or transaction expenses. Please note that Multiples of Invested Capital ("MOICs) are presented in this Presentation on the basis indicated.

In certain instances, the Gross IRR shown is a Concurrent IRR, meaning a gross annual IRR, calculated as if the first cash flow associated with all investments started in the same month.



